Drug Trial Radar · NCT03422653
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
Last checked: Nov 19, 2026Latest source record: Apr 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
378
Actual
Start
Feb 20, 2018
Primary completion
Apr 6, 2019
Study completion Mar 26, 2020
Sponsor
- Lead sponsor
- Cara Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week Double-blind Phase and a 52-week Open-label Extension Phase.
Conditions
- Uremic Pruritus
Interventions
CR845 0.5 mcg/kgDrug
IV medication delivered three times/week
PlaceboDrug
IV medication delivered three times/week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12Time frame: Week 12
Locations
57 sites in 1 country. Site status is shown where the registry gives one.
Cara Therapeutics Study Site
Homewood, Alabama
Cara Therapeutics Study Site
Huntsville, Alabama
Cara Therapeutics Study Site
Bakersfield, California
Cara Therapeutics Study Site 2
Beverly Hills, California
Cara Therapeutics Study Site
Beverly Hills, California
Cara Therapeutics Study Site
Chula Vista, California
Cara Therapeutics Study Site
Corona, California
Cara Therapeutics Study Site
Escondido, California
Cara Therapeutics Study Site
Fountain Valley, California
Cara Therapeutics
La Mesa, California
Cara Therapeutics Study Site
Long Beach, California
Cara Therapeutics Study Site
Ontario, California
Cara Therapeutics Study Site
Riverside, California
Cara Therapeutics Study Site
Roseville, California
Cara Therapeutics Study Site
San Diego, California
Cara Therapeutics Study Site
San Dimas, California
Cara Therapeutics Study Site
Tarzana, California
Cara Therapeutics Study Site
Denver, Colorado
Cara Therapeutics Study Site
Bridgeport, Connecticut
Cara Therapeutics Study Site
Hartford, Connecticut
Cara Therapeutics Study Site
Middlebury, Connecticut
Cara Therapeutics Study Site 1
Coral Springs, Florida
Cara Therapeutics Study Site
Hialeah, Florida
Cara Therapeutics Study Site
Miami, Florida
Cara Therapeutics Study Site
Miami Gardens, Florida
Cara Therapeutics Study Site
Tampa, Florida
Cara Therapeutics Study Site
Kalamazoo, Michigan
Cara Therapeutics Study Site
Roseville, Michigan
Cara Therapeutics Study Site
Minneapolis, Minnesota
Cara Therapeutics Study Site
Brookhaven, Mississippi
Cara Therapeutics Study Site
McComb, Mississippi
Cara Therapeutics Study Site
Tupelo, Mississippi
Cara Therapeutics Study Site
Kansas City, Missouri
Cara Therapeutics Study Site
Las Vegas, Nevada
Cara Therapeutics Study Site
Las Vegas, Nevada
Cara Therapeutics Study Site
Eatontown, New Jersey
Cara Therapeutics Study Site
Albuquerque, New Mexico
Cara Therapeutics Study Site
Gallup, New Mexico
Cara Therapeutics Study Site
Fresh Meadows, New York
Cara Therapeutics Study Site
Great Neck, New York
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.